Division of Pediatric Endocrinology, Children's Hospital of Philadelphia, PA, USA.
Department of Biostatistics and Medical Informatics, University of Wisconsin-Madison, Madison, WI, USA; Wisconsin Institute for Discovery, Madison, WI, USA.
Nutr Metab Cardiovasc Dis. 2020 Aug 28;30(9):1500-1511. doi: 10.1016/j.numecd.2020.05.001. Epub 2020 May 18.
Consumption of soy foods has been associated with protection against cardiometabolic disease, but the mechanisms are incompletely understood. We hypothesized that habitual soy food consumption associates with gut microbiome composition, metabolite production, and the interaction between diet, microbiota and metabolites.
We analyzed dietary soy intake, plasma and stool metabolites, and gut microbiome data from two independent cross-sectional samples of healthy US individuals (N = 75 lean or overweight, and N = 29 obese). Habitual soy intake associated with several circulating metabolites. There was a significant interaction between soy intake and gut microbiome composition, as defined by gut enterotype, on metabolites in plasma and stool. Soy consumption associated with reduced systolic blood pressure, but only in a subset of individuals defined by their gut microbiome enterotype, suggesting that responsiveness to soy may be dependent on microbiome composition. Soy intake was associated with differences in specific microbial taxa, including two taxa mapping to genus Dialister and Prevotella which appeared to be suppressed by high soy intake We identified context-dependent effects of these taxa, where presence of Prevotella was associated with higher blood pressure and a worse cardiometabolic profile, but only in the absence of Dialister.
The gut microbiome is an important intermediate in the interplay between dietary soy intake and systemic metabolism. Consumption of soy foods may shape the microbiome by suppressing specific taxa, and may protect against hypertension only in individuals with soy-responsive microbiota.
NCT02010359 at clinicaltrials.gov.
食用大豆食品与预防心血管代谢疾病有关,但机制尚不完全清楚。我们假设习惯性食用大豆食品与肠道微生物群落组成、代谢产物产生以及饮食、微生物群和代谢产物之间的相互作用有关。
我们分析了来自两个独立的美国健康个体横断面样本(N=75 名瘦或超重,N=29 名肥胖)的饮食中大豆摄入量、血浆和粪便代谢产物以及肠道微生物组数据。习惯性大豆摄入量与几种循环代谢物有关。大豆摄入量与肠道微生物群落组成(由肠道肠型定义)之间存在显著的相互作用,对血浆和粪便中的代谢物有影响。大豆消费与收缩压降低有关,但仅在一部分以肠道微生物组肠型定义的个体中,这表明对大豆的反应可能取决于微生物组的组成。大豆摄入量与特定微生物类群的差异有关,包括两个映射到属 Dialister 和 Prevotella 的类群,这些类群似乎被高大豆摄入量所抑制。我们确定了这些类群的上下文相关效应,其中 Prevotella 的存在与更高的血压和更差的心血管代谢特征有关,但仅在不存在 Dialister 的情况下才如此。
肠道微生物群是饮食中大豆摄入量和全身代谢之间相互作用的重要中间环节。食用大豆食品可能通过抑制特定的类群来塑造微生物群,并且只有在具有大豆反应性微生物群的个体中,才能预防高血压。
NCT02010359 在 clinicaltrials.gov。